Compare SLBT & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLBT | ADNT |
|---|---|---|
| Founded | N/A | 2016 |
| Country | Taiwan | Ireland |
| Employees | 20 | N/A |
| Industry | | Auto Parts:O.E.M. |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | 2016 |
| Metric | SLBT | ADNT |
|---|---|---|
| Price | $2.65 | $21.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.41 |
| AVG Volume (30 Days) | 145.3K | ★ 858.9K |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $17,439,000,000.00 |
| Revenue This Year | N/A | $2.71 |
| Revenue Next Year | N/A | $2.36 |
| P/E Ratio | ★ N/A | $366.75 |
| Revenue Growth | N/A | ★ 7.56 |
| 52 Week Low | $2.54 | $17.68 |
| 52 Week High | $6.25 | $27.32 |
| Indicator | SLBT | ADNT |
|---|---|---|
| Relative Strength Index (RSI) | 35.84 | 49.86 |
| Support Level | N/A | $20.23 |
| Resistance Level | $4.91 | $23.72 |
| Average True Range (ATR) | 0.37 | 0.91 |
| MACD | -0.14 | 0.21 |
| Stochastic Oscillator | 7.91 | 43.54 |
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.